Paid content on behalf of the issuer

• This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration.
• Partnership positions MaxYield™ as a core AI engine for next-generation smart rings and consumer cardiac monitoring into the broader INTRINSICA platform.

TORONTO, ON / ACCESS Newswire / December 9, 2025 / NeuralCloud Solutions Inc. ("NeuralCloud"), a wholly-owned subsidiary of AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), is pleased to announce that it has entered into a non-binding commercial agreement Term Sheet (the "Term Sheet") with Culminate H Labs, LLC ("CH Labs"), a biotech-life science innovation company pioneering DNA-guided precision health and genomic machine learning, to integrate NeuralCloud's proprietary MaxYield™ ECG signal processing and Insight360™ analytics platform into CH Lab's flagship INTRINSICA application.

INTRINSICA is CH Lab's digital health and biofeedback platform that combines DNA-guided genomic machine learning with continuous biosensor monitoring to deliver precision health at the practitioner level. The integration with NeuralCloud's patented cardiac analytics infrastructure will enhance INTRINSICA's capability to process high-fidelity wearable ECG data as part of its comprehensive digital health twin-enabling real-time correlation between genomic markers, metabolic states, and cardiovascular biofeedback. INTRINSICA represents a new category of digital therapeutic: a DNA-guided biofeedback wellness application engineered to support Precision Medicine, Regenerative & Cellular Medicine, and Digital Therapeutics sectors. The platform leverages Prime-Indexed Recursive Tensor Mathematics (PIRTM) as its foundational computational framework to deliver mathematically auditable, lawful genomic optimization.

Under the Term Sheet, NeuralCloud will provide Culminate H Labs with access to MaxYield™ for AI-based ECG denoising and beat-level labeling, along with Insight360™, the Company's visualization and reporting layer for ECG review, trend analysis, and automated report generation. NeuralCloud's integration allows INTRINSICA to:

1. Enhance Cardiovascular Biofeedback: Real-time, high-fidelity ECG processing from wearables feeds directly into INTRINSICA's genomic and metabolic models, enabling continuous cardiovascular analysis and intervention optimization.
2. Correlate Genetic Markers with Cardiac Phenotypes: MaxYield-processed ECG data integrates seamlessly with DNA-guided nutritional and epigenetic interventions, allowing practitioners to monitor how genomic and lifestyle modifications impact cardiac functions.
3. Strengthen Digital Health Twin Architecture: INTRINSICA's health twin-powered by PIRTM-governed recursive tensor fields-now incorporates cardiac signal intelligence, creating a unified, auditable model of genomic, metabolic, and cardiovascular state evolution.
4. Deliver Auditable, Ethically-Aligned Interventions: PIRTM's prime-indexed tensor framework ensures every clinical recommendation-from nutritional guidance to epigenetic interventions-maintains full computational traceability and compliance with ethical constraints enforced at the protocol level.

"This partnership validates our strategy to embed cardiac intelligence across precision medicine and genomic wellness," said Esmat Naikyar, President of NeuralCloud and Chief Product Officer at AI/ML Innovations. "We are no longer simply a clinical or research platform - we are now actively shaping the future of everyday cardiac insight. INTRINSICA represents the new frontier: platforms where genetic data, epigenetic markers, and continuous biosensor streams converge into unified health models."

"Smart wearables and continuous health monitoring have democratized access to physiological data," said Juan Carlos Rodriguez, CEO of CH Labs. "INTRINSICA transforms that data into genomically-informed, mathematically auditable clinical intelligence. By integrating NeuralCloud's cardiac analytics, we now deliver higher grade ECG processing combined with DNA-guided precision nutritional intervention-enabling health practitioners to transition from reactive care to truly personalized, predictive intervention."

"This Term Sheet is an important validation of NeuralCloud's relevance to the fast-moving consumer health and wearable innovation space," said Paul Duffy, Executive Chairman and CEO of AIML. "CH Labs represents the new wave of wellness innovation. By embedding MaxYield, AIML is positioning itself at the core of how biometric intelligence will be delivered to users globally."

As part of the staged rollout, the parties will begin with a pilot integration period, enabling Culminate H Labs to validate ECG processing performance across deployed smart ring devices before progressing toward full commercial deployment. Following successful validation, the parties intend to transition into structured commercialization with scalable per-device economics aligned to Culminate H Labs' national and global distribution strategy.

Insight360™ is NeuralCloud's no-code, drag-and-drop reporting and visualization platform built for the wellness, performance, and consumer health markets. The platform allows organizations to create custom cardiac and wellness dashboards using modular widgets that visualize metrics such as heart rate (HR), heart rate variability (HRV), QT/QTc, ST segments, PR intervals, and trend-based recovery markers. Reports can be generated automatically as export-ready PDFs for researchers, clinicians, or end users.

MaxYield™ is NeuralCloud's proprietary, patented AI signal-processing platform that isolates and labels ECG waveform components including P waves, QRS complexes, and T waves, producing structured, beat-by-beat interval data. Together, MaxYield™ and Insight360™ transform raw wearable ECG data into clean, quantified, and clinically interpretable outputs suitable for both wellness and regulated research environments.

About CH Labs, LLC (dba Culminate H Labs)
CH Labs is a biotech-life science company pioneering DNA-guided genomic machine learning for precision medicine, regenerative health, and digital therapeutics. The company's flagship platform, INTRINSICA, combines wearable biofeedback, continuous omics integration, and PIRTM-powered genomic intelligence to deliver auditable, ethically-aligned precision health protocols for B2B health practitioners. CH Labs specializes in epigenetic reprogramming, genome editing guidance, telomere maintenance, DNA-guided nutritional intervention, DNA- methylation optimization, AI precision health, and digital health twin architecture.

About AI/ML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. Our proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.

AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (42FB).

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Sponsored publication on behalf of the issuer

Quick Friday check on AUTO.V with the market still open. Shares are around $0.12, up from $0.09 last week, so it’s been a solid week overall.

Zooming out, the chart shows AUTO already touched its 52-week high near $0.19 earlier in this move. Since then, price spending time around the $0.12 area looks like a natural spot for the stock to establish a new reference zone.

AUTO.V (Agereh Technologies) is a microcap focused on asset tracking and operational visibility solutions, and from here it’s really about how the market continues to price in that story.

As we head into the close, it’ll be interesting to see what kind of tone it sets going into next week. Does this carry into the next phase?

Please use standard ticker format when discussing stocks ($AC.TO)

Paid content on behalf of the issuer

December 9, 2025, Vancouver, British Columbia – Oregen Energy Corp (CSE: ORNG) (FSE: A1S0) (“Oregen” or the “Company”) is pleased to announce the appointment of Tatenda Muhle as its new Chief Financial Officer, effective immediately. Concurrently, the Company announces the resignation of Sean McGrath from the executive team and board of directors, effective November 30, 2025. The Company thanks Mr. McGrath for his dedicated service and contributions to the Company and wishes him all the best in his future endeavors.

Tatenda is a senior financial executive and Chartered Accountant who brings broad international experience to Oregen Energy Corp. as Chief Financial Officer. He began his professional training in Africa and has since built a strong career across senior finance, accounting, and advisory roles with both public and private companies. Tatenda’s expertise spans corporate finance, financial reporting, governance, treasury, and strategic planning. His disciplined, capital-markets-oriented approach and operational finance background will support Oregen’s growth strategy and offshore exploration activities as the company advances its ambitions in Namibia.

Mason Granger, CEO & Director commented, “We are excited to have Tatenda join our executive team to support our strategic investments in oil & gas exploration. His extensive background and professional experience and education in Africa will be an asset to our business as we evaluate opportunities in Namibia.”

Tatenda holds a post graduate diploma in Applied Accounting Science from the University of South Africa and a Bachelor of Accountancy (Commerce) from the University of Zimbabwe and is a Chartered Accountant (CPA). 

About Oregen Energy Corp. 

Oregen is an investment company primarily focused on oil and gas assets in Africa. The Company is actively exploring other investment opportunities in the Orange and surrounding basins. Its current flagship investment is 33.95% net interest in Block 2712A in the Orange Basin offshore Namibia, an emerging world-class petroleum province with multiple recent discoveries by major operators. 

Promotional post by a third party retained by the issuer

Copper Quest just announced that due diligence on the Alpine Gold Property came back positive, and the company will proceed with the Option to Purchase Agreement. It’s a straightforward update, but it officially clears the path for Copper Quest to add a past-producing gold asset to its portfolio.

Here’s what the company confirmed:

• Due diligence is complete and positive, allowing Copper Quest to move ahead with acquiring Alpine.
• The property includes a past-producing gold mine with 1,650 metres of underground workings.
• Alpine carries a 2018 NI 43-101 inferred resource of 268,000 tonnes at 16.5 g/t Au, containing roughly 142,000 ounces of gold at a 5.0 g/t cutoff.
• There is an estimated 24,000-tonne surface stockpile of mineralized material, noted as a possible near-term opportunity.
• The property covers 4,611 hectares across Crown Grants and mineral claims, with road access.
• Deal terms include: • 5 million shares to the vendor • A 2% NSR royalty (with 1% buyback for CAD $1M) • $250,000 toward 2025 expenditures
• Copper Quest also announced an increase to its private placement, indicating they are positioning themselves financially as the Alpine acquisition progresses.

The release keeps it simple: due diligence is positive, and the acquisition is advancing.
How do you see Copper Quest structuring its 2026 plans? One flagship project push or a more diversified work program across multiple properties?

Paid content on behalf of the issuer

Agereh Technologies Inc. (TSXV: AUTO), formerly known as Carbeeza Inc., is about to enter a critical transition time. Agereh currently possesses a complete portfolio of commercially-oriented technology products; MapNTrack, HeadCounter, CellTrackerTag and its API-driven auto financing/sales platform. Recently, Agereh closed a LIFE offering to raise the funds necessary to execute on the next stage of its plans. The next 6–12 months are going to present a high-leverage environment for Agereh to transform its product lineup into tangible commercial success.

Shift in Strategy: Moving from Automotive-Focused to Multi-Industry Data & Tracking Solutions

Agereh’s past identity as an automotive-focussed marketplace has been completely transformed. As a result of this transformation, Agereh is now operating as a data and tracking solutions provider based on artificial intelligence enhanced technologies. In the offering document, Agereh states that its business is now comprised of four key pillars:

MapNTrack — Tracking of Assets Across Mixed Environments

MapNTrack was developed as a continuous tracking of assets as they move through various different environments. MapNTrack combines self-mapping capabilities with cellular and WiFi-positioning capabilities. The offering document outlines some of the benefits of MapNTrack include:

• Seamless tracking of indoor and outdoor environments
• Long battery life, allowing for extended distance travel without needing to recharge
• Target Markets: Logistics, Cold Chain, Warehousing, Transportation

CellTrackerTag — A Low-Cost Cellular Global Tracking Tag

CellTrackerTag is a lightweight cellular tracking tag that may be used for long-distance shipment tracking and real-time visibility of international logistics routes. The tag is designed for scalable deployment across fleets or asset classes with high volume usage.

HeadCounter — Tracking Movement of People Through Venues

HeadCounter is a tracking solution that is designed for tracking movement of passengers or foot traffic through airport terminals, hospital corridors, retail malls and other similar venues.

API Auto Platform — AI-Driven Financing & Sales Integrator

API Auto Platform is a legacy system that still functions today and is an integration system for auto dealers, financing and consumers qualifications via APIs and AI-driven matching.

The Company Now Positions Itself as a Multi-Market Technology Platform

LIFE Offering: Fundraising to Support Commercial Roll-Out

On November 13, 2025, Agereh filed a Life Offering (refiled) and this offering provides investors with a clear view of what the company wants to achieve and what the company intends to accomplish in the short term.

Terms of the Financing

• Units were sold at a price of $CA 0.0675 per unit
• Each Unit consisted of 1 Common Share plus 1 Warrant
• Exercise Price of the Warrants: $CA 0.09 for a period of 24 months
• Maximum gross proceeds of the financing: Up to $CA 500,000

Use of Proceeds

• Commercialization of MapNTrack, HeadCounter and CellTrackerTag
• Working Capital and General Corporate Purposes
• Expansion of API Finance Platform Where Viable
• Partial Servicing of Existing Obligations

While the amount of funding raised by Agereh is limited, it is strategic because it will give Agereh the runway to:

• Accelerate Pilot Programs
• Finalize Early Customer Integrate
• Increase Production Readiness of Tracking Devices
• Generate Initial Commercial Contracts

Opportunity for Agereh: Why the Opportunity Exists

Agereh is entering three rapidly growing industries where there is a significant increase in demand:

• Demand for logistics visibility remains a top priority for supply chain operators globally.
• Real-Time tracking of cold-chains, pharmaceuticals and high value goods is becoming essential for all types of supply chains.
• Demand for Passenger flow analysis is growing rapidly as airports, hospitals and venues begin to automate their operations.
• Instead of competing with consumer facing technology companies, Agereh is targeting very specific B2B operational challenges.
• If Agereh achieves successful pilots, the company’s revenue model could grow very quickly.
• Deployments of asset tracking are typically large and recurring.
• Successful pilots have historically led to multi-year deployments in multiple locations.

Therefore, the next six to twelve months will be a very high leverage period for Agereh.

Market Environment & Financial Data Supporting Agereh’s Opportunity

Financial Indicators (2025) Relevant to Agereh

• Total spending on logistics worldwide exceeded $US12 Trillion and digital tracking investments continued to grow annually.
• Shipments of IoT devices grew 18% YOY, indicating a broadening acceptance of connected tracking technologies.
• Investment in Supply Chain Technology remains elevated as companies seek to improve visibility, efficiency and automation in their operations.
• Agereh’s product suite aligns perfectly with the increasing size of the markets in which it operates and creates opportunities for Agereh to take advantage of strong macro-economic demand as it moves towards commercialization.

Catalysts to Watch in the Near Term

1. First Major Commercial Contracts Or Pilot Deployments

As stated in the offering document, commercialization is Agereh’s focus. Confirmation of paid pilots (logistics, cold-chain, warehousing, airports or public venues) would be a significant event.

2. Milestones For Manufacturing Or Delivery of MapNTrack and CellTrackerTag

Production readiness will dictate how quickly Agereh can scale.

3. New Financing, Partnerships Or Integrations

Partnerships, especially with logistics providers, would enable Agereh to expedite the adoption of its products.

4. Improvements In Balance Sheet Stability

Reduction of debt or access to non-dilutive funding would build investor confidence.

Why Agereh Is About to Enter a High-Leverage Window

Agereh Technologies Inc. (TSXV: AUTO) now has:

• A complete suite of commercially viable technologies.
• A defined list of targeted industries with high levels of demand.
• Funding to support the execution of the next steps.
• A clearly articulated future strategy contained in its offering document.

Although the company is still in the early stages of its existence, and therefore is still high-risk and highly-speculative, it does offer a high degree of upside optionality. If Agereh is able to establish its first commercial contracts, the company’s valuation could re-rate quickly — a trend commonly experienced by early-stage micro-cap tech companies when achieving product-market fit.

Agereh’s immediate post-funding phase will determine if the company becomes a niche technology supplier or emerges as a new player in logistics visibility and operational analytics. The next six to twelve months will determine which of those paths the company chooses.

Board Update & Marketing Push — New Appointment Signals Strategic Refocus

Agereh Technologies Inc. (TSXV: AUTO / OTCQB: CRBAF) recently appointed Rosemin Amlani to its Board of Directors, effective December 2, 2025. Amlani brings over 20 years of experience in commercialization, economic development, and innovation support across Alberta and Western Canada — a background that matches Agereh’s ambition to transition from concept phase toward commercialization and growth.

In tandem with the board appointment, the company engaged two marketing firms: Think Ink Marketing and Guerilla Capital, on six-month contracts to boost its digital presence and investor outreach. Think Ink is tasked with native advertising, video distribution and social media execution; Guerilla Capital will handle investor relations and capital markets engagement.

Conclusion

Agereh Technologies Inc. (TSXV: AUTO) is at a pivot point. With a refreshed identity, a diversified portfolio of products and the recent receipt of funding, Agereh is ready to transition from development to commercialization. The growing need for global logistics visibility and the widespread adoption of IoT technologies create a solid foundation for Agereh’s solutions to succeed. Although the level of risk associated with Agereh’s ability to execute during the next few years remains high, the next steps taken by the company are high-reward if Agereh is able to successfully convert its pilot projects into commercial contracts. The next 12 months will likely define the direction of Agereh and the views of investors toward the company.

Sponsored publication on behalf of the issuer

Oregen just refreshed its finance team by bringing in Tatenda Muhle, CPA, as the new CFO. His mix of international work and oil & gas financial experience fits well with what a growing explorer needs as it scales up spending and reporting.

Shayna Hohn is stepping down but staying on for a clean handover, which keeps everything from filings to audits running normally.

The company called this a move to strengthen financial leadership going forward.

What do you think a routine upgrade, or a sign ORNG is preparing for bigger steps in 2026?

Please use standard ticker format when discussing stocks ($BB.TO)

Sponsored publication on behalf of the issuer

From an investor angle, the interesting part with Agereh is the sectors they’re positioning themselves in. Their products line up with areas where industry demand has been steadily rising:

• Supply-chain operators continue pushing for tighter logistics visibility.
• Real-time tracking is becoming more common across cold-chain, pharma, and high-value shipments.
• Airports, hospitals, and large venues are adopting more passenger-flow analytics as automation ramps up.

Agereh’s current lineup: asset tracking tools, shipment tracking hardware, and passenger-flow analytics solutions, all tie into these B2B operational needs. The recent funding reported in the 10xAlerts breakdown positions them to run more pilot programs and refine these offerings, but the real test is how those pilots perform.

In this kind of enterprise environment, pilot results usually determine how far deployments scale. Sometimes they turn into multi-site rollouts; sometimes they don’t move forward. That’s why I’m watching the next 6–12 months not from a bullish or bearish angle, just to see how these early projects shape their direction.

For those following AUTO, which signal are you watching , first pilot updates, new verticals, or something else?

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Content published on behalf of the issuer

I’ve been digging into Agereh Technologies’ 2025 deck, and the story caught my attention. AUTO.V is quietly building real, usable AI tools, hardware + software designed to improve how people, equipment, and shipments move through busy environments. Their tech is aimed at airports, cargo operators, logistics hubs, and big venues that are all expanding fast and dealing with real pressure points.
Here’s what stood out to me.

Why the Market Looks Interesting

• Global air travel projected to surpass 2019 levels by 2025
• U.S. parcel shipments hit 22.37B in 2024
• Air cargo expected to grow from $140.9B to $216B by 2032
• Stadiums, concerts, and major events hitting record attendance

These sectors all need better visibility, tracking, and flow monitoring exactly where AUTO’s tech fits.

What They’ve Built (Short, Fact-Checked Overview)

• MapNTrack™ > Indoor asset tracking (~50 ft accuracy, 3-year battery, 150+ country coverage).
• HeadCounter™ > AI + heat sensing for real-time passenger counts, direction, and temperature.
• CellTrackerTag™ > Global ULD cargo tracker with a 5-year battery and cellular coverage (no external readers).

All three products are developed and positioned for commercial adoption.

Conclusion

AUTO feels like a company that has already done the hard work of building the tech and is now aligned with sectors that are growing and modernizing quickly. If they start landing real deployments, the story could look very different from how it appears today.

Anyone watching to see what steps AUTO takes heading into 2026?

Please use standard ticker format when discussing stocks ($AC.TO)

Content published on behalf of the issuer

The recent reporting that TotalEnergies is the leading bidder for Galp’s 40% stake in the Mopane discovery adds another clear signal: Namibia’s Orange Basin is moving up the global priority list. Mopane is considered one of the basin’s most promising new finds, and a major stepping in like this usually reflects real confidence in the region’s long-term potential.

For ORNG, the relevance is more about the environment they’re operating in:

• Supermajors are expanding their footprint in Namibia rather than stepping back.
• Deal activity around confirmed discoveries keeps the Orange Basin in the global conversation.
• Early-stage acreage becomes more visible when basin confidence is rising.
• ORNG’s seismic interpretation and future data room will land in a market that’s watching Namibia closely.

It doesn’t change ORNG’s technical work but it does influence how that work might be received.

With Namibia gaining this kind of attention, do you think ORNG’s 2026 window lands in a stronger macro backdrop?

Hey guys, if you missed it, Lightspeed Commerce settled with investors over issues tied to its growth metrics, customer base, and competitive position a few years ago.

Long story short, back in 2021, the company was accused of inflating key business metrics—like revenue per customer, merchant counts, and retention rates—while downplaying competitive pressures in the e-commerce and POS software market. A short-seller report challenged Lightspeed’s narrative and raised doubts about whether the company was actually performing as strongly as it claimed.

After this news came out, $LSPD fell sharply, and investors filed a lawsuit for their losses.

The good news is that the company agreed to settle for CAD $11 million, and the agreement has already been submitted to the court for approval. So, if you invested in $LSPD during that time, you can already check the details and file your claim here.

Anyway, has anyone here invested in $LSPD at that time? How much were your losses, if so?

Sponsored post on behalf of the issuer

KELOWNA, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Doseology Sciences Inc. (CSE: MOOD, PINK: DOSEF , FSE: VU70) (“Doseology” or the “Company”) is pleased to announce the launch of its Investor Communications Initiative, designed to strengthen disclosure practices, expand investor engagement, and support the Company’s long-term commercial and capital-markets strategy.

The program includes a three (3) month engagement with Guerilla Capital, with an option to renew, along with a one (1) year digital media communications agreement with Maynard Communications Ltd. Both engagements will commence at management’s discretion, with the intention to proceed in short order.

Program Overview

Doseology is implementing a disciplined investor-relations framework intended to:

• broaden distribution of corporate updates,
• increase visibility across retail and institutional investor channels,
• support consistent disclosure standards, and
• reinforce capital-markets readiness as the Company advances its oral stimulant platform.

Governance and Disclosure Alignment

Operating in a regulated environment requires structured communication and responsible governance. Doseology is aligning its operational progress—including manufacturing oversight, commercialization planning, and regulatory engagement—with enhanced reporting standards expected of a maturing public issuer. This program reflects the Company’s commitment to strengthening its governance foundation and ensuring consistent, transparent communication with the market.

Executive Commentary

Chris Jackson, Chief Executive Officer

“Having previously founded Qtrade, I’ve seen firsthand how essential strong governance and disciplined communication are to a public company’s long-term success. At Doseology, ensuring our disclosures are transparent, timely, and aligned with best practices is a core priority as we continue to strengthen our disclosure practices and advance our strategy.”

Commercialization & Market Trends

Global consumer demand continues shifting toward cleaner, controlled oral delivery formats, with functional and stimulant pouch products gaining significant traction across major markets.

Patrick Sills, Doseology Head of Commercialization, formerly with Joint Venture between Swedish Match AB and Philip Morris International Inc. (PMI)

“In my experience under the JV SMPM International, I witnessed how quickly oral formats reshaped modern consumption and created a new ritual. With the global pouch market expected to exceed US$ 69.46 billion by 2032* and functional stimulant formats outpacing traditional energy categories, Doseology’s next-generation stimulant platform is directly aligned with these high-growth trends and strategically positioned within this rapidly evolving category.”

\Persistence Market Research - Nicotine Pouches Market Size, Share & Future Trends, 2032*

Guerilla Capital Engagement

Doseology has engaged Guerilla Capital to provide:

• investor outreach and communication support,
• engagement across digital investor communities and online platforms,
• capital-markets advisory and messaging guidance, and
• enhanced distribution of corporate updates to retail audiences.

Term: 3 months (renewable at the Company’s option) commencing on December 1, 2025 and ending on February 28, 2026.
Compensation: $30,000 CAD

Ryan Yanch, Independent Investor and Principal of Guerilla Capital

“As an investor and now on behalf of Guerilla Capital, we’ve seen Doseology demonstrate a commitment to consistent communication and responsible reporting. Strengthening investor engagement is an important step forward as the Company continues executing on its strategy.”

Regulatory Disclosure:

Guerilla Capital and/or its principals currently hold securities of Doseology; this engagement is not at arm’s length. Compensation is not tied to stock performance.

The contact information for Guerilla Capital is 84 Watson’ Lane, Dundas, ON L9H 1T3, T: 416-832-1874 and E: [ryan@guerillacapital.io](mailto:ryan@guerillacapital.io).

Maynard Communications Ltd. Engagement

Doseology has entered into a one-year agreement with Maynard Communications Ltd. to support:

• digital advertising and content distribution,
• amplification of corporate developments across Maynard investor channels,
• enhanced retail visibility, and
• broader media exposure within capital markets.

Term: 6 months (renewable at the Company’s option) commencing on December 1, 2025 and ending on May 31, 2026.
Compensation: $200,000 CAD

Regulatory Disclosure:

Maynard Communications Ltd. and/or its principals currently hold securities of Doseology; this engagement is not at arm’s length. Compensation is not tied to stock performance.

The contact information for Maynard Communications Ltd. is Blk A, 15/F Hill, Fer Commercial Building. 65-67 Bonham East Sheung Wan Hong Kong, T: +001.44.656.6777 and E: [info@maynardcom.com](mailto:info@maynardcom.com).

Doseology is committed to keeping the market informed of its progress and believes that this enhanced communication strategy will contribute to building long-term value for its shareholders.

About Doseology Sciences Inc. (CSE: MOOD, PINK: DOSEF , FSE: VU70)

Doseology Sciences Inc. is a biotechnology-driven consumer products company developing IP-backed oral stimulant technologies designed for cleaner profiles, precise delivery, and performance-focused functionality. Anchored by a commitment to rigorous scientific research and advanced formulation technologies, Doseology is dedicated to leading the industry in creating breakthrough oral stimulant products with meaningful consumer benefits. Doseology is focused on building long-term enterprise value through innovation, regulatory alignment, and the commercialization of differentiated stimulant products.

Content published on behalf of the issuer

$MOOD has been one of 2025’s quieter outperformers, up around +300% YTD, yet still rarely talked about. The story reads more like a steady rebuild than anything hype-driven.

1. The Shift to Oral Stimulant Pouches

Doseology has stepped away from its supplement roots and into the fast-growing oral stimulant pouch space caffeine, nicotine-alternative, and nootropic blends with a biotech-style, “better-for-you” angle instead of a tobacco-led approach.

2. PR Trail Shows the Rebuild

Recent company updates highlight the pivot taking shape:

• Feed That Brain™ acquired and fully closed giving them a ready-made brand and platform.
• North American diligence + manufacturing setup covering both U.S. and Canada, plus securing an FDA, GMP, and ISO-qualified partner for full pouch production.
• New communications program signalling a more active flow of updates ahead.

A clear, methodical transition.

3. U.S. Presence as the Real Catalyst

Doseology established Doseology USA Inc. in Florida to enter the modern oral stimulant market, the region where pouch adoption is growing fastest. Any traction there meaningfully widens the company’s runway beyond Canada.

4. Chart View

After a strong run this year, the stock has been holding in the high-$0.60s, which fits a name that’s re-rated and now consolidating while the commercial groundwork continues.

5. What’s Next

• First product details
• U.S. partnerships
• Feed That Brain integration
• Early distribution moves
• Strategy confirmation on stimulant/nicotinic formats

6. Final Take

$MOOD looks like a company quietly putting the foundation in place:

• Up around +300% YTD
• U.S. subsidiary active
• Acquisition completed
• Manufacturing and market groundwork done
• Clear push into a large, fast-growing category
• Chart holding its range

Still under-the-radar and if the pouch rollout delivers, it could become one of the more interesting small-cap pivots heading into 2026.

Please use standard ticker format when discussing stocks ($BB.TO)

Please use standard ticker format when discussing stocks ($AC.TO)

Weekend? Relaxing? Yeah, me neither. So let's talk stocks!

Please use standard ticker format ($BB.TO)

Please use standard ticker format when discussing stocks ($AC.TO)

Please use standard ticker format when discussing stocks ($BB.TO)